摘要
目的:探讨多索茶碱联合布地奈德福莫特罗治疗对慢性阻塞性肺疾病(COPD)患者血气指标及肺功能的影响。方法:选取2019年1月-2021年1月廉江市人民医院收治的86例COPD患者,按随机数字表法分为两组,各43例。对照组予以布地奈德福莫特罗治疗,观察组在对照组基础上加用多索茶碱治疗。比较两组血气指标、肺功能指标、炎症因子水平及不良反应发生情况。结果:观察组治疗后氧分压(PaO_(2))较对照组高,二氧化碳分压(PaCO_(2))较对照组低,差异均有统计学意义(P<0.05);观察组治疗后用力肺活量(FVC)、最大呼气峰流速(PEF)及第一秒用力呼气容积(FEV_(1))/FVC%均高于对照组,差异均有统计学意义(P<0.05);观察组治疗后肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)均较对照组低,差异均有统计学意义(P<0.05);两组不良反应相比,差异无统计学意义(P>0.05)。结论:多索茶碱联合布地奈德福莫特罗可增强COPD治疗效果,改善动脉血气状况,减轻气道炎症反应,促进患者肺功能恢复,安全可靠。
Objective:To explore the effect of Doxofylline combined with Budesonide Formotero on blood gas indexes and lung function in patients with chronic obstructive pulmonary disease(COPD).Method:A total of 86 patients with COPD admitted to People’s Hospital of Lianjiang City from January 2019 to January 2021 were randomly divided into two groups with 43 cases in each group.The control group was treated with Budesonide Formoterol,and the observation group was treated with Doxofylline on the basis of the control group.The blood gas indexes,lung function indexes,inflammatory factor levels and adverse reactions were compared between the two groups.Result:After treatment,the partial pressure of oxygen(PaO_(2))in the observation group was higher than that in the control group,and the partial pressure of carbon dioxide(PaCO_(2))in the observation group was lower than that in the control group,with statistical differences(P<0.05);forced vital capacity(FVC),maximum peak expiratory flow rate(PEF)and forced expiratory volume in the first second(FEV_(1))/FVC%in the observation group after treatment were higher than those in the control group,the differences were statistically significant(P<0.05).Tumor necrosis factor-α(TNF-α)and interleukin-8(IL-8)in the observation group were lower than those in the control group after treatment,with statistical differences(P<0.05).There was no significant difference in ADR between the two groups(P>0.05).Conclusion:The combination of Doxofylline and Budesonide Formoterol can enhance the efficacy of treatment of COPD,improve the condition of arterial blood gas,reduce airway inflammation,and promote the recovery of lung function in patients,which is safe and reliable.
作者
吴豪智
陈荟鹏
庞天秀
WU Haozhi;CHEN Huipeng;PANG Tianxiu(People’s Hospital of Lianjiang City,Guangdong Province,Lianjiang 524400,China;不详)
出处
《中国医学创新》
CAS
2022年第5期50-53,共4页
Medical Innovation of China
